Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Weekly Bortezomib in Relapsed/Refractory Multiple Myeloma
NCT00536575Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Nov 2007
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in multiple myeloma (MM), sponsored by SCRI Development Innovations. Started Nov 2007; status: completed.
02
Drugs
sorafenib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00536575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00536575.